Companies
Recipharm
Recipharm (founded 1995, Sweden) is investing multi-million sums in US sterile manufacturing, a new BFS line and high-potency OSD at Leganés, sharpening its access-enabling footprint.
- Country
- Sweden
Commercial
Sterile + OSD CDMO
Coverage
| CN | EU | IN | US | |
|---|---|---|---|---|
| market-access-commercial | ✓ | ✓ | ✓ | ✓ |
Regulatorsfdaemanmpa
Verifiable facts
| Fact | Value | Source |
|---|---|---|
| Revenue | €827 million (2024) | firstwordpharma.com · recipharm.com |
| Headcount | over 5,000 employees | recipharm.com |
| Production site | Global network includes facilities in France, Germany, India, Israel, Italy, Morocco, Portugal, Spain, Sweden, and the US | recipharm.com |
| Funding | Multi-million dollar investments in US sterile manufacturing, new BFS line, and high-potency OSD capabilities at Leganés (2026) | recipharm.com |
| Regulatory approval | Secured multiple FDA and global regulatory approvals (2024) | recipharm.com |
| Regulatory approval | Leganés site is FDA-approved and holds AEMPS, ANVISA, EMA, PMDA, and MFDS certifications | recipharm.com |
| Capacity | Increased pre-filled syringes (PFS) and lyophilisation capacity across Europe and the US; Wasserburg site offers over 60 million PFS and vial capacity; added over 100 million ready-to-use sterile units in the US | recipharm.com |
Independent sources: firstwordpharma.com
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Local manufacturing for market access | market-access-commercial | Low | → |
Compiled by BIOECON from primary sources.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.